PCI Biotech AS of Oslo, Norway, has appointed Per Walday as its new chief executive officer, effective in the second quarter of 2008. He will replace Anders Høgset, who is to become chief scientific officer.
Mr Walday is currently global head of project management at GE Healthcare.
PCI Biotech is a subsidiary of Photocure ASA which develops and sells pharmaceuticals and medical devices based on its photodynamic technology. PCI has developed a method for the light-directed delivery of therapeutic molecules to tumour cells. Photocure owns 91.4% of PCI. The remaining shares are held by the research foundation of the Radium Hospital and employees of the company.
Source:
Photocure press release, 1 February 2008
Copyright 2008 Evernow Publishing Ltd